PCM
PTCT icon

Price Capital Management’s PTC Therapeutics PTCT Stock Holding History

Price Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,361
Closed -$205K – 166
2015
Q1 		$205K Sell
3,361
-21,857
-87% -$1.33M 0.13% 300
2014
Q4 		$1.31M Buy
+25,218
New +$1.11M 1.15% 40

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Price Capital Management's PTCT Position: Q2 2015 in Review

Price Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2015, closing a stake of 3,361 shares — an estimated $205K sold.

Price Capital Management first reported a position in PTCT in Q4 2014 and held it in 2 quarters. The position peaked at $1.31M in Q4 2014. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

  • Price Capital Management reported no remaining PTC Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 3,361 PTC Therapeutics shares in Q2 2015, an estimated $205K.
  • Price Capital Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 2 quarters.
  • Price Capital Management's PTC Therapeutics position peaked at $1.31M in Q4 2014.
  • 155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.